
    
      Participants will be randomized into 4 arms:

      AR51 (12, 10): arm receiving vaccine formulation containing 12 mcg of polyribosylribitol
      phosphate (PRP) conjugates to tetanus toxoid (PRP-T) and 10 mcg of Hepatitis B surface
      antigen (HBsAg)

      PR51 (3, 10): arm receiving vaccine formulation containing 3 mcg of PRP conjugated to the
      outer membrane protein complex of Neisseria meningitides (PRP-OMPC) and 10 mcg of HBsAg

      PR51 (6, 10): arm receiving vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of
      HBsAg

      PR51 (6, 15): arm receiving vaccine formulation containing 6 mcg of PRP-OMPC and 15 mcg of
      HBsAg
    
  